scholarly journals Incidence and Risk Factors for Metabolic Syndrome in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients-a Tertiary Care Center Experience

2015 ◽  
Vol 21 (2) ◽  
pp. S171-S172
Author(s):  
Surabhi Batra ◽  
Karina Danner-Koptik ◽  
Morris Kletzel
Keyword(s):  
Risk Factors ◽  
Metabolic Syndrome ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
Care Center ◽  
Tertiary Care ◽  
Cell Transplant ◽  
Tertiary Care Center ◽  
Hematopoietic Stem

scholarly journals Risk Factors for Falls with Injury for Patients Admitted for Hematopoietic Stem Cell Transplant

2014 ◽  
Vol 20 (2) ◽  
pp. S197
Author(s):  
Anne M. McDonnell ◽  
Brett Glotzbecker ◽  
Robert J. Soiffer ◽  
Joseph H. Antin ◽  
Edwin P. Alyea ◽  
...  
Keyword(s):  
Risk Factors ◽  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Hematopoietic Stem ◽  
Risk Factors For Falls

Clinical Characteristics and Outcomes of Breakthrough Candidemia in 71 Hematologic Malignancy Patients and/or Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Single-center Retrospective Study From China, 2011–2018

2020 ◽  
Vol 71 (Supplement_4) ◽  
pp. S394-S399
Author(s):  
Xiao-Chen Chen ◽  
Jie Xu ◽  
De-Pei Wu
Keyword(s):  
Risk Factors ◽  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Single Center ◽  
Allogeneic Transplant ◽  
Hematopoietic Stem ◽  
Incidence And Mortality

Abstract Background Antifungal prophylaxis may result in breakthrough infections in hematology patients with severe agranulocytosis, with few studies assessing risk factors and clinical outcomes of breakthrough candidemia. We described the distribution of Candida species, assessed risk factors for mortality in such patients, and determined differences in the incidence and mortality of breakthrough candidemia between patients who did or did not receive an allogeneic hematopoietic stem cell transplant. Methods We collected clinical and microbiological data of patients with hematologic malignancies and breakthrough candidemia from a single center. Seven-day and 30-day follow-up outcomes were recorded; the incidence and mortality of breakthrough candidemia between patients who did or did not undergo an allogeneic transplant were compared. Kaplan-Meier survival estimates were used to generate survival curves, and predictors were identified using Cox regression analyses. Results Of 71 enrolled patients, 17 received allogeneic transplants. Incidences of breakthrough candidemia were 17 of 2924 (0.58%) and 54 of 12 015 (0.45%) in the transplant and nontransplant groups, respectively (P = .35). The most common isolate was Candida tropicalis, and antifungal agent combinations were the most common first-line treatment. Cumulative mortality rates of patients were 21.1% and 31.0% at days 7 and 30, respectively, and they significantly differed between both groups. Septic shock, central venous catheter removal, and granulocyte recovery were significantly associated with 7-day mortality; the latter 2 remained independent predictors of 30-day mortality. Conclusions Breakthrough candidemia-related mortality was higher in the allogeneic transplant group, although the incidence was not significantly different between the groups. Prompt and adequate antifungal treatment with catheter removal may reduce mortality.

scholarly journals Clinical Characteristics and Risk Factors for Adverse Outcomes of Influenza Infections in Hematopoietic Stem Cell Transplant Recipients

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 22-22
Author(s):  
Brian J. Chernak ◽  
Emily Coskun ◽  
Nina Orfali ◽  
Yuqing Qiu ◽  
Rosemary Soave ◽  
...  
Keyword(s):  
Risk Factors ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
Vaccination Status ◽  
Adverse Outcomes ◽  
Positive Test ◽  
Cell Transplant ◽  
Hematopoietic Stem ◽  
Graft Versus Host

Background: As one of the most prevalent pathogens in the environment, influenza affects millions of patients annually and contributed to tens of thousands of deaths in the United States during 2018-2019 alone. Immune deficiency is one of the most significant risk factors for adverse outcomes in adults with influenza, and similarly infectious complications are one of the most common causes of death in hematopoietic stem cell transplant (HSCT) recipients. However, data on outcomes or risk factors for progression in influenza infections specifically in HSCT recipients are limited. Methods: We reviewed patient demographics, oncology and transplant history from HSCT recipients with polymerase chain reaction (PCR)-confirmed influenza over 5 influenza seasons (from 2013-2014 through 2018-2019). Influenza subtype (A H1, H3, and B), laboratory studies at diagnosis, treatments, vaccination status, and outcomes for each influenza infection were recorded and analyzed. Results: A total of 143 infection events were collected and analyzed for symptoms and outcomes. Influenza infections of each subtype occurred in each season, although a different strain predominated each season. The most common symptoms at presentation were cough (65.3%) and fever (55.2%). Symptoms at presentation and outcomes were not significantly different amongst Influenza type A H1, A H3 and type B infections (p>0.05). In total, 22 (15.4%) infections presented as lower respiratory tract infections (LRTIs) and 7 additional infections progressed to LRTIs (all LRTI: 29; 20.1%). 63 (44.1%) infected patients required hospital admission, 15 (10.5%) required transfer to the intensive care unit (ICU) and 8 (5.6%) were intubated. 6 patients (4.2%) died by 30 days after the initial positive test, and 23 (16.1%) died by 180 days. LRTI was significantly associated with hospital admission (p<0.001), transfer to the ICU (p<0.001), intubation (p=0.005), and 30-day mortality (p=0.016); it was not significantly associated with 180-day mortality (0.357). The chronic use of steroids within the past 30 days prior to the initial positive test was significantly associated with risk of presenting with a LRTI (p=0.009), all LRTI (p=0.017), admission (p=0.010), and both 30-day (p=0.027) and 180-day mortality (p=0.016). It was not significantly associated with transfer to the ICU (p>0.05) or intubation (p>0.05). No other factors were significantly associated with LRTI, including vaccination status or treatment with antivirals (p>0.05). Logistic regression analysis of selected factors found that patients receiving steroids were significantly associated with LRTI (OR 2.58: 95% CI 1.00-6.63; p=0.047) (Table 1). There was, however, no statistically significant association detected between active graft-versus-host disease and LRTI (OR 1.25: 95% CI 0.35-4.06; p=0.721). We also found that treatment with oseltamivir within 2 days of symptom onset was not significantly associated with LRTI (OR 1.42: 95% CI 0.59-3.49; p=0.431). Persistent shedding (positive tests longer than 21 days from initial positive test) was also not associated with adverse outcomes (p>0.05). Conclusion: This study suggests that the use of chronic steroids in treatment for graft-versus-host disease in HSCT patients may increase the risk for adverse outcomes in influenza infections. Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document